What to do when metformin monotherapy isn't enough

WITH a plethora of new medicines on the market, new guidelines to be published and emerging clinical outcome data, the management of diabetes continues to evolve. However, what hasn’t changed is importance of an individualised, stepped approach to ensure patients achieve their glycaemic targets while minimising risk of hypoglycaemia.1 For patients not achieving adequate glycaemic control with lifestyle modifications and metformin, guidelines continue to recommend sulfonylureas as the usual initial second-line options.1-4 Sulfonylureas achieve similar reductions in HbA1c compared to other second-line oral agents,3,5,